Axovan

About Axovan

Axovan AG, established in 2000, was a Swiss biopharmaceutical company that carved a niche in the drug discovery sector. Based in Allschwil, the firm concentrated its efforts on the complex field of G Protein-Coupled Receptors (GPCRs), a critical family of receptors involved in cellular communication. The company's core business involved operating a fully functional drug discovery platform designed to identify, engineer, and refine small chemical molecules capable of interacting with GPCRs to address various human pathologies.

The company's journey began with a seed funding round of SFr8 million in June 2000 from a consortium of Swiss investors, including New Medical Technologies (now part of HBM BioVentures), Venture Partners AG, Genevest, and notably, Actelion, which would later play a pivotal role in its history. A significant Series B financing round followed in April 2002, securing SFr30 million led by Atlas Venture, which enabled Axovan to accelerate its development programs. By the time of its acquisition, Axovan's most advanced asset was clazosentan, a drug candidate licensed from Roche Holding AG aimed at preventing cerebral vasospasm following a specific type of brain hemorrhage, which had progressed to Phase II clinical trials.

Dr. Olivier Valdenaire served as the CEO and was tasked with overseeing the company's integration post-acquisition. Another key figure associated with the founding team was Dr. Philippe Dro, who later became the CEO of Luciole Medical. This focus on specialized drug discovery attracted substantial venture capital backing, totaling over $23.3 million across two rounds from investors such as Atlas Venture, Heidelberg Innovation, NeoMed, and Banque Cantonale Vaudoise Private Equity.

The company's trajectory culminated in its acquisition by Actelion, a larger biopharmaceutical firm with a similar research focus, announced in September 2003. The transaction had an initial value of approximately $190 million (CHF 60 million), with the potential to increase based on the successful advancement of its product pipeline. The acquisition represented a strategic move by Actelion to complement its internal research and development efforts, leveraging Axovan's specialized platform and drug candidates.